Dr Martens' chief executive Guy Fordham signed off on a refreshed growth plan that widens the brand beyond its signature boot line. The board believes the shift will reduce the group's dependence on traditional leather boots, which have faced slowing demand in Europe and North America. Management expects the broader catalogue to capture younger, fashion‑forward shoppers. The initiative targets a 2025 revenue lift.

The strategic pivot follows a two‑year slump that saw revenue dip 4% as sneaker competitors eroded market share. Analysts note that Dr Martens' inventory turnover improved after the company introduced casual shoes and limited‑edition collaborations in 2022. By diversifying the product mix, the firm aims to stabilise margins and offset seasonal volatility tied to its core boot segment. Margin pressure remains a concern.

Investors welcomed the plan, sending the stock up 3% in early trading as confidence returned to the balance sheet. The move also aligns with a broader industry trend of heritage brands expanding into lifestyle categories to sustain growth. With the new product rollout scheduled for the summer, Dr Martens will test whether the broader footwear range can deliver a lasting uplift.